甲状腺功能减退的个体化治疗:左甲状腺素对所有人都足够吗?
本文综述左甲状腺素(LT4)治疗背景下甲状腺激素代谢异常的证据,探讨部分患者持续存在症状的原因及LT4与碘塞罗宁(LT3)联合治疗的作用。多数LT4治疗患者血清促甲状腺激素正常化后T3/T4比值下降、T3水平相对较低,至少15%病例血清T3低于正常。作者建议在排除其他原因后,对促甲状腺激素正常化但仍有持续症状或代谢异常的患者,公开讨论并考虑LT4与LT3联合治疗。
要点
- 多数LT4治疗患者促甲状腺激素正常化后血清T3/T4比值下降,T3水平相对较低。
- 至少15%的LT4治疗病例血清T3水平低于正常。
- 作者建议对促甲状腺激素正常化但仍有持续症状或代谢异常者,排除其他原因后考虑LT4与LT3联合治疗。
核心结论
- 在排除其他原因后,医生应与促甲状腺激素水平正常化但仍存在持续症状或代谢异常的甲状腺功能减退患者公开讨论并考虑LT4与LT3联合治疗。
研究设计与样本
- 本综述基于PubMed检索「hypothyroidism」「levothyroxine」「liothyronine」「desiccated thyroid extract」等关键词收集的原始文献与综述文献,并辅以Google Scholar检索及作者既往知识。
主要发现
- 多数LT4治疗患者血清促甲状腺激素正常化后出现血清T3/T4比值下降,血清T3水平相对较低。
- 至少15%的病例血清T3水平低于正常。
- 这些变化可导致甲状腺激素作用减弱,可解释代谢速率减慢和血清胆固醇水平升高。
- 小部分患者可能经历持续的甲状腺功能减退症状,包括认知受损和疲倦。
- 作者提出此类患者携带关键临床因素(如特定遗传和/或免疫组成),在甲状腺功能正常时被良好代偿,但与相对较低的血清T3水平叠加时可能显现。
临床怎么用
- 作者建议:在排除其他原因后,医生应与促甲状腺激素水平正常化但仍存在持续症状或代谢异常的甲状腺功能减退患者公开讨论并考虑LT4与LT3联合治疗。
局限性
- 需要新的临床试验,聚焦有症状患者、遗传组成和合并症,并具备识别单药治疗与联合治疗差异的统计学效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: It is well recognized that some hypothyroid patients on levothyroxine (LT4) remain symptomatic, but why patients are susceptible to this condition, why symptoms persist, and what is the role of combination therapy with LT4 and liothyronine (LT3), are questions that remain unclear. Here we explore evidence of abnormal thyroid hormone (TH) metabolism in LT4-treated patients, and offer a rationale for why some patients perceive LT4 therapy as a failure. EVIDENCE ACQUISITION: This review is based on a collection of primary and review literature gathered from a PubMed search of "hypothyroidism," "levothyroxine," "liothyronine," and "desiccated thyroid extract," among other keywords. PubMed searches were supplemented by Google Scholar and the authors' prior knowledge of the subject. EVIDENCE SYNTHESIS: In most LT4-treated patients, normalization of serum thyrotropin levels results in decreased serum T3/T4 ratio, with relatively lower serum T3 levels; in at least 15% of the cases, serum T3 levels are below normal. These changes can lead to a reduction in TH action, which would explain the slower rate of metabolism and elevated serum cholesterol levels. A small percentage of patients might also experience persistent symptoms of hypothyroidism, with impaired cognition and tiredness. We propose that such patients carry a key clinical factor, for example, specific genetic and/or immunologic makeup, that is well compensated while the thyroid function is normal but might become apparent when compounded with relatively lower serum T3 levels. CONCLUSIONS: After excluding other explanations, physicians should openly discuss and consider therapy with LT4 and LT3 with those hypothyroid patients who have persistent symptoms or metabolic abnormalities despite normalization of serum thyrotropin level. New clinical trials focused on symptomatic patients, genetic makeup, and comorbidities, with the statistical power to identify differences between monotherapy and combination therapy, are needed.
引用
- Ettleson MD, Bianco AC. Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone? J Clin Endocrinol Metab. 2020. PMID: 32614450. doi:10.1210/clinem/dgaa430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。